GlycoVaxyn AG, a privately-owned Swiss biotechnology company, has raised CHF 25 million in a Series B financing to support the clinical development of its lead vaccine candidate for intestinal infections. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals
